Answers are grounded in this paper and cite their sources.
This editorial provides an overview of recent pivotal trials and registries in interventional cardiology, emphasizing the importance of rigorous trial design and placebo controls.
For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts. Since its introduction by Andreas Grüntzig, percutaneous coronary intervention1 (PCI) has made impressive progress, with the refinement of balloons, monorail systems, guidewires, stents,2,3 and other devices. As a result, the therapeutic options and outcomes have improved considerably. Open questions remain though, for instance regarding management of complex bifurcation lesions. Should we pursue a provisional stent or two stent technique?4 Also if two stents are used, is T-stenting,5 culotte,6 or the crush technique better?7 This is again addressed in the ‘Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial’ by Shao-Liang Chen and colleagues from the Nanjing Medical University in China.8 The authors randomized 653 patients with complex bifurcation lesions to either a systematic two-stent technique or provisional stenting. At the 1-year follow-up, target lesion failure occurred in 11.4% and 6.1% in the provisional and two-stent groups, respectively, largely driven by increased target vessel myocardial infarction and clinically driven target lesion revascularization in the provisional group (Figure 1). Cardiac death rate was comparable between groups. It would appear that for complex coronary bifurcation lesions, the systematic two-stent approach provides better clinical outcomes compared with provisional stenting. As outlined in the Editorial by Franz-Josef Neumann from the Universitäts-Herzzentrum Freiburg – Bad Krozingen in Germany, further studies are warranted to better characterize the patient profile and mechanisms contributing to the increased rate of target vessel myocardial infarction after provisional stenting.9 For patients with complex bifurcation lesions defined by the DEFINITION criteria, systematic two-stent approaches were associated with a significant reduction of target lesion failure, compared with provisional stenting strategies. CI, confidence interval; HR, hazard ratio; TLF, target lesion failure; TLR, target lesion revascularization; TVMI, target vesselmyocardial infarction (from Zhang J-J, Ye F, Xu K, Kan J, Tao L, Santoso T, Munawar M, Tresukosol D, Li L, Sheiban I, Li F, Tian N-L, Rodríguez AE, Paiboon C, Lavarra F, Lu S, Vichairuangthum K, Zeng H, Chen L, Zhang R, Ding S, Gao F, Jin Z, Hong L, Ma L, Wen S, Wu X, Yang S, Yin W-H, Zhang J, Wang Y, Zheng Y, Zhou L, Zhou L, Zhu Y, Xu T, Wang X, Qu H, Tian Y, Lin S, Liu L, Lu Q, Li Q, Li B, Jiang Q, Han L, Gan G, Yu M, Pan D, Shang Z, Zhao Y, Liu Z, Yuan Y, Chen C, Stone GW, Han Y, Chen S-L. Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial. See pages 2523–2536). For patients with complex bifurcation lesions defined by the DEFINITION criteria, systematic two-stent approaches were associated with a significant reduction of target lesion failure, compared with provisional stenting strategies. CI, confidence interval; HR, hazard ratio; TLF, target lesion failure; TLR, target lesion revascularization; TVMI, target vesselmyocardial infarction (from Zhang J-J, Ye F, Xu K, Kan J, Tao L, Santoso T, Munawar M, Tresukosol D, Li L, Sheiban I, Li F, Tian N-L, Rodríguez AE, Paiboon C, Lavarra F, Lu S, Vichairuangthum K, Zeng H, Chen L, Zhang R, Ding S, Gao F, Jin Z, Hong L, Ma L, Wen S, Wu X, Yang S, Yin W-H, Zhang J, Wang Y, Zheng Y, Zhou L, Zhou L, Zhu Y, Xu T, Wang X, Qu H, Tian Y, Lin S, Liu L, Lu Q, Li Q, Li B, Jiang Q, Han L, Gan G, Yu M, Pan D, Shang Z, Zhao Y, Liu Z, Yuan Y, Chen C, Stone GW, Han Y, Chen S-L. Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial. See pages 2523–2536). Crosstalk between clinical practice (bottom left), available infrastructure (upper left) and clinical outcomes (right) in the EAPCI Atlas Countries. PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve intervention; CVD, cardiovascular disease (from Barbato E, Noc M, Baumbach A, Dudek D, Bunc M, Skalidis E, Banning A, Legutko J, Witt N, Pan M, Tilsted H-H, Nef H, Tarantini G, Kazakiewicz D, Huculeci R, Cook S, Magdy A, Desmet W, Cayla G, Vinereanu D, Voskuil M, Goktekin O, Vardas P, Timmis A, Haude M. Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Atlas Project. See pages 2579–2588). Crosstalk between clinical practice (bottom left), available infrastructure (upper left) and clinical outcomes (right) in the EAPCI Atlas Countries. PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve intervention; CVD, cardiovascular disease (from Barbato E, Noc M, Baumbach A, Dudek D, Bunc M, Skalidis E, Banning A, Legutko J, Witt N, Pan M, Tilsted H-H, Nef H, Tarantini G, Kazakiewicz D, Huculeci R, Cook S, Magdy A, Desmet W, Cayla G, Vinereanu D, Voskuil M, Goktekin O, Vardas P, Timmis A, Haude M. Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Atlas Project. See pages 2579–2588). Peripheral percutaneous interventions are equally important, but have their own characteristics.10 Drug-coated balloons for femoropopliteal interventions are commonly used and often coated with paclitaxel, the safety of which has been called into question, but recently cleared by a huge real-world registry.11 However, the drug dosage remains an issue, and such drug-coated balloons have not been tested against each other. In their Fast Track article entitled ‘COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions’, Dierk Scheinert and colleagues from the University of Leipzig – Heart Center in Germany report a comparison of the efficacy and safety of high dose (In.Pact™) vs. low dose (Ranger™) drug-coated balloons with nominal paclitaxel densities of 3.5 μg/mm2 vs. 2.0 μg/mm2.12 In this prospective, multicentre, non-inferiority trial, 414 patients with symptomatic femoropopliteal lesions (Rutherford classification 2–4) were randomly assigned to one of the balloons after stratification for lesion length. Total occlusions were observed in >40%, and provisional stenting was performed in every fourth intervention. Primary patency was 81.5% in the high dose and 83.0% in the low dose drug-coated balloon group. Freedom from major adverse events was 92.6% with high dose and 91.0% with low dose drug-coated balloons. Overall death rate was low (2.0%), and no major amputation occurred. Thus, the two drug-coated balloons with different coating characteristics exhibited comparable results, with excellent effectiveness and safety through 12 months for femoropopliteal interventions including a wide range of lesion lengths. These results are put into context in an Editorial by Carlo Di Mario and Francesco Liistro from the University Hospital Careggi in Florence, Italy.13 Clinical trials in interventional cardiology are much more challenging than drug trials, particularly if compared with a drug treatment or placebo arm. The difference in the benefit of invasive cardiovascular interventions compared with placebo controls, however, has not been analysed systematically. For their meta-analysis ‘Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis’ Felix Mahfoud and colleagues from the Universitätsklinikum des Saarlandes in Homburg, Germany searched through MEDLINE and Web of Science up to 29 March 2020.14 Randomized, placebo-controlled trials of catheter-based interventions and pacemaker-like devices were included. Thirty trials, comprising 4102 patients, were analysed. The overall risk of bias was judged to be low in only 43% of the trials. Ten trials, or 33%, demonstrated statistically significant superiority of invasive interventions over placebo for their pre-defined primary outcomes. In almost half of the 16 trials investigating continuous pre-defined primary outcomes, the standardized mean differences between the active and placebo procedure indicated a small (n = 4) to moderate (n = 3) treatment effect of active treatment over placebo. In contrast, one trial indicated a small treatment effect in favour of placebo. In the remaining trials, there was no relevant treatment effect of active treatment over placebo. In trials with a protocol-mandated stable and symmetrical use of co-interventions, the superiority of active procedures vs. invasive placebo procedures was significantly larger as compared with trials with frequent or unbalanced changes in co-interventions. Thus, the incremental treatment effect of invasive cardiovascular interventions compared with placebo controls was small in most trials, a result that is further discussed in an Editorial by Anthony N. DeMaria and colleagues from the University of California in La Jolla, California, USA.15 The availability of large datasets from multiple sources (e.g. registries,16 biobanks,17,18 electronic health records, claims or billing databases, implantable devices,19 wearable sensors20,21 (and mobile apps), coupled with advances in computing and analytic technologies, have provided new opportunities for conducting innovative health research. This is discussed in a Current Opinion ‘Understanding the use of observational and randomized data in cardiovascular medicine’ by Barbara Casadei and colleagues from the John Radcliffe Hospital in Oxford, UK.22 Improved digital access to health information has facilitated the conduct of efficient randomized controlled trials upon which clinical management decisions can be based, for instance, by permitting the identification of eligible patients for recruitment and/or linkage for follow-up via their electronic health records. Given these advances in cardiovascular data science and their complexities, it is important that health professionals have clarity on the appropriate use and interpretation of observational, so-called ‘real-world’, and randomized data in cardiovascular medicine. The European Society of Cardiology has initiated the Atlas Programme to provide data on cardiovascular disease and cardiology practice in Europe.23 The latest product is the EAPCI Atlas of Interventional Cardiology that has been developed to map practice across ESC member countries. In the contribution entitled ‘Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Atlas Project’ Emanuele Barbato and colleagues present the main findings of a 16-country survey in which they examine the national availability of interventional infrastructure resources and procedural volumes of PCI and structural interventions.24 Sixteen countries participated in the survey, providing a representative cross-section of the ESC national membership with data collected by the National Cardiac Society of each participating country. An annual mean of 4954 (median 5131) diagnostic cardiac catheterizations per million people were reported, ranging from <2500 in Egypt and Romania to >7000 in Turkey and Germany. Procedure rates showed weak but significant correlation with gross national income per capita, but there was no correlation with national ‘need’ as determined by the prevalence of ischaemic heart disease. An annual mean of 2247 (median 2478) PCIs per million people were reported, ranging from <1000 in Egypt and Romania to >3000 in Switzerland, Poland, and Germany. Again, procedure rates showed weak but significant correlation with gross national income per capita, but no correlation with the prevalence of ischaemic heart disease. An average of 73 (median 48) transcatheter aortic valve implantations (TAVIs) per million inhabitants were performed, varying from <25 per million people in Egypt, Romania, Turkey, and Poland to >100 per million people in Denmark, France, Switzerland, and Germany. Procedure rates again correlated with national gross national income per capita. Thus, the EAPCI Atlas shows considerable international heterogeneity in interventional cardiology procedure rates. Surprisingly, the heterogeneity was not a response to national differences in the prevalence of cardiovascular disease, but was driven more by national economic resources, a reflection no doubt of the technological costs of developing an interventional cardiology service. Finally, this issue also contains the ESC Report ‘Implementing the new European Regulations on medical devices—clinical responsibilities for evidence-based practice: a report from the Regulatory Affairs Committee of the European Society of Cardiology’ by Alan Fraser from Cardiff University in the UK, and colleagues. The new European Union (EU) law governing the regulatory approval of medical devices will now take effect as of May 2021. Consequently, clinical evidence for any high-risk device must be reported by the manufacturer in a Summary of Safety and Clinical Performance (SSCP) that will be publicly available; this will facilitate evidence-based recommendations. Hospitals must record all device implantations, and each high-risk device will be trackable by Unique Device Identification (UDI). EU Expert Panels will scrutinize clinical data submitted by manufacturers. They will advise manufacturers on the design of their clinical studies and recommend to regulators when new technical specifications or guidance are needed. Physicians should support post-market surveillance by reporting adverse events and by contributing to comprehensive medical device registries. A second law on In vitro Diagnostic Medical Devices will take effect from 2022. All healthcare professionals should contribute proactively to these new systems, in order to enhance the efficacy and safety of high-risk devices and to promote equitable access to effective innovations. The issue is complemented by various Discussion Forum contributions. In the first one entitled ‘Accuracy of fractional flow reserve during acute myocardial infarction’ Rahman Shah from UT Memphis in Memphis, Tennessee (USA) comments on the recent publication entitled ‘Fractional flow reserve in clinical practice: from wire-based invasive measurement to image-based computation’ from Shengxian Tu and colleagues from Shanghai Jiao Tong University in Shanghai, China.25,26 Tu and colleagues respond in a separate comment.27 In a further contribution ‘Coronary interventions in Austria, Germany, and Switzerland’ Hanno Ulmer from the Innsbruck Medical University in Austria on behalf of the Austrian National CathLab Registry ANCALAR comments on the recent ‘European Society of Cardiology: Cardiovascular Disease Statistics 2019’.28,29 A final Discussion Forum contribution entitled ‘Air pollution is intimately linked to global climate change: change in Cardiovascular Disease Statistics 2019’ by Alberto Dominguez-Rodriguez and colleagues from the Hospital Universitario de Canarias in Tenerife, Spain also comments on the same publication.30 The editors hope that readers of this issue of the European Heart Journal will find it of interest. With thanks to Amelia Meier-Batschelet for help with compilation of this article.
No takes yet. Share an insight, caveat, or question.
Thomas F. Lüscher (2020) conducted an editorial in complex coronary bifurcation lesions (n=653). Systematic two-stent technique vs. Provisional stenting was evaluated on Target lesion failure.
Synapse has enriched 10 related papers. Consider them for comparative context: